Indication
Treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
Medicine details
- Medicine name:
- ravulizumab (Ultomiris)
- SMC ID:
- SMC2330
- Pharmaceutical company
- Alexion Pharma UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- Q2 2021
- SMC meeting date:
- Q2 2021
- Patient group submission deadline:
- 01 February 2021